A Phase 2a study of BAER-101
Latest Information Update: 16 Aug 2024
At a glance
- Drugs AZD 7325 (Primary)
- Indications Epilepsy; Partial epilepsies; Seizures
- Focus Therapeutic Use
- Sponsors Avenue Therapeutics
Most Recent Events
- 09 Aug 2024 According to an Avenue Therapeutics media release, subject to the receipt of additional financing, Avenue continues plans to initiate a Phase 2a clinical trial of BAER-101 in patients with focal epilepsy and other seizure disorders.
- 04 Aug 2023 New trial record
- 01 Aug 2023 According to an Avenue Therapeutics media release, company will initiating a Phase 2a study of BAER-101 in 2024.